Partners in Financial Planning Acquires New Stake in Edwards Lifesciences Co. (NYSE:EW)

Partners in Financial Planning purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,584 shares of the medical research company’s stock, valued at approximately $858,000.

A number of other large investors have also recently modified their holdings of EW. Harbor Capital Advisors Inc. grew its position in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after acquiring an additional 273 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its stake in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $4,845,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several recent research reports. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Truist Financial restated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Citigroup lifted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.95.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock worth $4,513,064 in the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.4 %

Shares of NYSE:EW opened at $70.90 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $71.49 and a two-hundred day simple moving average of $70.53. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.73. The stock has a market capitalization of $41.68 billion, a price-to-earnings ratio of 10.17, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.